Welcome to our dedicated page for Mereo Biopharma SEC filings (Ticker: MREO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Mereo BioPharma Group plc (NASDAQ: MREO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other documents filed with the Securities and Exchange Commission. These filings offer primary-source information on Mereo’s financial condition, clinical development updates, and material corporate events.
Mereo’s Form 8-K filings, for example, have furnished press releases covering quarterly financial results, cash and cash equivalents, and recent corporate highlights. They also describe key clinical milestones, such as the progress of the Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta, Data Monitoring Committee recommendations to proceed to final analysis, and subsequent top-line results. Other 8-K reports outline developments in the company’s pipeline, including partnering activities and regulatory designations for alvelestat in alpha-1 antitrypsin deficiency-associated lung disease.
Through this page, users can follow how Mereo reports its operating performance, research and development spending, and capital structure over time via its SEC submissions. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, 10-Ks or 10-Qs without reading every line.
Investors interested in MREO can use the filings page to monitor material updates on clinical programs, financing, and corporate agreements as they are reported to the SEC. Real-time access, combined with AI-generated explanations, supports efficient review of Mereo BioPharma’s regulatory history and ongoing disclosure record.
Mereo BioPharma Group plc is convening its 2026 Annual General Meeting on May 14, 2026 to ask shareholders to approve eleven resolutions, including authority to allot shares and disapply pre-emption rights up to a maximum nominal amount of £3,591,354.73 expiring on June 30, 2029.
The meeting materials include the Company’s U.K. statutory annual report and accounts for the year ended December 31, 2025, re-appointment of PwC as auditor, approval of remuneration-related proposals, re-election of three directors, and references a Form S-3 shelf registration effective May 22, 2024 permitting ADS offerings up to $175 million. Shares outstanding were 798,078,829 as of April 7, 2026.
Mereo BioPharma Group plc reported that Dr. Annalisa Jenkins has informed the company she will not stand for re-election to its Board of Directors at the 2026 annual general meeting of shareholders scheduled for May 14, 2026.
She will continue to serve as a director until her current term expires immediately prior to that meeting. The company stated that Dr. Jenkins’ decision is not due to any disagreement with the company or the board regarding operations, policies, or practices, indicating a planned transition rather than a dispute-driven departure.
Mereo BioPharma Group plc files its annual report describing a rare‑disease focused biopharma business built around late‑stage assets setrusumab for osteogenesis imperfecta and alvelestat for severe alpha‑1 antitrypsin deficiency‑associated lung disease.
The company reports that two Phase 3 pediatric and young adult studies of setrusumab (Orbit and Cosmic) did not achieve statistical significance on their primary fracture‑reduction endpoints, although both met secondary endpoints with strong improvements in bone mineral density versus comparators and maintained a consistent safety profile. Further analyses are underway to determine next regulatory steps.
Alvelestat has shown positive Phase 2 biomarker and symptom data in AATD‑LD and is being advanced toward a single global Phase 3 trial, with alignment from U.S. and European regulators on primary endpoints. Mereo also highlights multiple partnering deals (Ultragenyx, āshibio, ReproNovo, Feng Biosciences) and ongoing royalty‑ and milestone‑based economics, while emphasizing risks around funding needs, clinical trial execution, intellectual property, and continued Nasdaq listing. As of June 30, 2025, non‑affiliate equity market value was approximately $368,470,120, and 798,078,829 ordinary shares were outstanding as of March 18, 2026.
Mereo BioPharma reported a 2025 net loss of $41.9M, slightly improved from $43.3M in 2024, on $0.5M of revenue. Research and development expenses fell to $17.8M and general and administrative costs to $23.0M, reflecting lower spending on alvelestat, etigilimab and corporate functions.
Cash and cash equivalents were $41.0M as of December 31, 2025, down from $69.8M a year earlier, which the company expects to fund operations into mid‑2027. Shareholders’ equity stood at $40.9M.
In its pipeline, the Phase 3 Orbit and Cosmic studies of osteoporosis drug setrusumab in osteogenesis imperfecta did not meet primary fracture endpoints but showed strong bone mineral density gains, vertebral fracture reductions and positive patient‑reported outcomes, with further analyses ongoing. For alvelestat, Mereo has aligned with regulators on a single ~220‑patient Phase 3 trial in AATD‑lung disease and designed a potential Phase 2b bronchiectasis study to support partnering. The company also outlicensed vantictumab for osteopetrosis to āshibio, which plans a Phase 2 study in the second half of 2026.
Jacquet Pierre reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Pierre Jacquet reported equity awards rather than open‑market trades. He received share options for 66,000 shares at a price of $0.00 per share and 106,848 deferred restricted stock units, both recorded as direct beneficial ownership.
The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date. The deferred restricted stock units are granted in lieu of annual cash compensation, vest monthly over the following plan year, and are generally settled in American Depositary Shares about 180 days after separation of service. Each ADS represents five ordinary shares.
Mereo BioPharma Group plc director Marc J. Yoskowitz reported equity compensation awards. He received share options covering 66,000 shares at an exercise price of $0.0000 per share, classified as a grant or award acquisition.
He was also granted 96,163 deferred restricted stock units, which are provided in the form of American Depositary Shares instead of annual cash compensation. The options vest in substantially equal monthly installments over one year from the February 26, 2026 grant date, while the deferred restricted stock units vest in substantially equal monthly installments over the plan year and are generally settled in ADSs 180 days after separation of service.
Shames Daniel reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Daniel Shames reported receiving new equity awards. On February 26, 2026, he was granted 66,000 share options and 96,163 deferred restricted stock units as compensation. The options vest in substantially equal monthly installments over one year from the grant date.
The deferred restricted stock units are granted in the form of American Depositary Shares instead of annual cash compensation for non-executive directors and also vest in substantially equal monthly installments over the plan year. Each ADS represents five ordinary shares of Mereo BioPharma Group plc.
Ekblom Anders reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Anders Ekblom reported equity awards that increase his potential ownership stake. He received share options for 66,000 shares at a price of $0.0000 per share and 133,560 deferred restricted stock units, both granted on February 26, 2026.
The options vest in substantially equal monthly installments over one year from the grant date. The deferred restricted stock units were elected in lieu of annual cash compensation and also vest in substantially equal monthly installments over the plan year, with settlement in American Depositary Shares, where each ADS represents five ordinary shares, generally 180 days after separation of service.
Mereo BioPharma Group plc director Jeremy Bender reported equity awards rather than open-market trades. On February 26, 2026, he received share options for 66,000 shares at a price of $0.00 per share, vesting in substantially equal monthly installments over one year from the grant date.
He also acquired 117,533 deferred restricted stock units, granted in lieu of annual cash compensation, which vest in substantially equal monthly installments over the plan year following the grant date. Each American Depositary Share represents five ordinary shares, and payment of these deferred units in ADSs will generally occur 180 days after separation of service.
PAKIANATHAN DEEPIKA reported acquisition or exercise transactions in this Form 4 filing.
Mereo BioPharma Group plc director Deepika Pakianathan was granted share options covering 66,000 shares on February 26, 2026. The options have a right to buy the company’s shares at a price of $0.0000 per share.
The grant vests in substantially equal monthly installments over one year from the February 26, 2026 grant date, meaning portions of the award become exercisable each month during that period.